ClinicalTrials.gg
CompletedNCT05442554Updated Sep 18, 2025Results posted

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

A Phase 4 interventional study of Brentuximab vedotin in T-Cell Lymphoma, sponsored by Takeda. Completed at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, T-Cell.

Enrollment
10th of 12
10 · median 36
Started
2022
the only one that year
Phase 4
2 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Takeda

Among the 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 4, and was the 12th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

1 of the 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Lymphoma, T-Cell studies recruiting now, 41 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, or all of them as a file.
02

Study summary

The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults.

Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.

Read the detailed description

The drug being tested in this study is called brentuximab vedotin (SGN-35). Brentuximab vedotin is being tested to treat people who have CD30-positive cutaneous T-Cell lymphoma.

The study will enroll approximately 10 patients. Participants will receive a single treatment i.e., brentuximab vedotin monotherapy:

  • Brentuximab vedotin 1.8 mg/kg

Participants will be administered with brentuximab vedotin by intravenous (IV) infusion given for approximately 30 minutes on Day 1 of each 21-day cycle up to 16 cycles followed by the end of treatment (EOT) visit 30 days after receiving the final dose of study drug. Participants with progressive disease (PD) at any time during the study will be discontinued from study drug.

This multi-center trial will be conducted in China. Participants will remain in this study for approximately 56 weeks.

03

Conditions studied

  • T-Cell Lymphoma

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. - confirmed cluster of differentiation antigen 30 positive (CD30+) disease by local laboratory assessment and pathology review.

2. Participants with primary cutaneous anaplastic large cell lymphoma (pcALCL) who have received prior radiation therapy or at least 1 prior systemic therapy, or participants with mycosis fungoides (MF) who have received at least 1 prior systemic therapy for their disease. 3. (ECOG) performance status of ≤2. 4. Suitable venous access for the study-required blood sampling. 5. Participants must have radiographically or clinically measurable or evaluable disease.

6. Recovered (i.e., Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy.

Exclusion criteria

-Exclusion Criteria:

  1. A concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL), or other non-Hodgkin lymphoma (excluding lymphomatoid papulosis [LyP]).
  2. A concurrent diagnosis of sézary syndrome (SS) or high blood tumor burden (B2) disease.
  3. therapy for the treatment of cutaneous T-cell lymphoma (CTCL) within 3 weeks of first dose of study drug.
  4. Known to recombinant proteins, murine proteins, or any contained in the drug formulation.
  5. Life-threatening illness unrelated to cancer.
  6. Severe central nervous system (CNS), pulmonary, renal, or hepatic disease not related to the participant's cancer.
  7. Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML).
  8. Known (HIV) positive.
  9. Known surface antigen positive or known or suspected active infection.
  10. Any severe active systemic viral, bacterial, or fungal infection within 1 week before first study drug dose requiring systemic antimicrobial therapy. (Oral antibiotics for prophylaxis are allowed.)
  11. Receiving antibody-directed or immunoglobulin-based immune therapy (eg, immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first study drug dose.
  12. Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug:

    • Myocardial infarction within 6 months of enrollment.
    • (NYHA) Class III or IV heart failure.
    • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  13. History of another primary not in remission for at least 3 years. The following are exempt from the 3-year limit: completely resected in situ carcinoma, such as nonmelanoma skin cancer and cervical carcinoma in situ on or a squamous intraepithelial lesion on Pap smear.
  14. Oral retinoid therapy for any indication within 3 weeks of the first dose of study drug.
  15. History of pancreatitis or significant risk factors for developing pancreatitis (eg, prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin

    Participants received brentuximab vedotin 1.8 milligrams per kilogram (mg/kg), IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.

    Drug: Brentuximab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL

    ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) that lasts at least 4 months. CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral involvement using computed tomography (CT) scan, and for the participants with mycosis fungoides (MF) only, detection of circulating Sezary cells. Response Criteria were based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines.

    Time frame: Up to 58 weeks

Secondary outcomes

  1. Complete Response (CR) Rate

    CR rate is defined as the percentage of participants with CR. CR is defined as complete disappearance of all clinical evidence of disease. CR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using computed tomography (CT) scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.

    Time frame: Up to 58 weeks

  2. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using CT scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.

    Time frame: Up to 58 weeks

  3. Duration of Response (DOR)

    Duration of response was assessed in participants with CR or PR and is defined as the time between first documentation of response and progressive disease (PD). Response criteria were based on ISCL, USCLC and EORTC Consensus guidelines. Participants who were lost to follow-up, withdrew consent, or discontinued treatment due to undocumented PD after the last adequate disease assessment were censored at the last disease assessment.

    Time frame: Up to 58 weeks

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g. a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE and SAE were determined as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (up to approximately 58 weeks)

  5. Changes From Baseline in Participant's Vital Sign: Systolic and Diastolic Blood Pressure

    Vital signs included seated blood pressure (systolic and diastolic) measurements.

    Time frame: Baseline, at end of treatment (approximately Week 54)

  6. Changes From Baseline in Participant's Vital Sign: Heart Rate

    Vital signs included heart rate (beats per minute) measurements.

    Time frame: Baseline, at end of treatment (approximately Week 54)

  7. Changes From Baseline in Participant's Vital Sign: Body Temperature

    Vital signs included body temperature (degree Celsius) measurements.

    Time frame: Baseline, at end of treatment (approximately Week 54)

  8. Number of Participants From Baseline to Worst Post-Baseline Assessment Categories Based on Eastern Cooperative Oncology Group (ECOG) Performance Status Scale

    ECOG scale was used to assess performance status of participants. Grades range from 0 (fully active) to 5 (dead) where Grade 0: Normal activity. Grade 1: Symptoms but ambulatory. Grade 2: In bed \<50% of the time. Grade 3: In bed \>50% of the time. Grade 4: 100% bedridden. Grade 5: Dead. Lower grades indicate improvement. Reported here is the number of participants in each reported baseline grade to their worst post-baseline grade assessment on the ECOG scale.

    Time frame: Baseline up to 30 days after the last dose of study drug (up to approximately 58 weeks)

  9. Change From Baseline in Hematology Parameter: Hemoglobin

    Time frame: Baseline, at end of treatment (approximately Week 54)

  10. Change From Baseline in Hematology Parameter: Neutrophil Count

    Time frame: Baseline, at end of treatment (approximately Week 54)

  11. Change From Baseline in Hematology Parameter: Platelet Count

    Time frame: Baseline, at end of treatment (approximately Week 54)

  12. Change From Baseline in Hematology Parameter: Lymphocyte Count

    Time frame: Baseline, at end of treatment (approximately Week 54)

  13. Change From Baseline in Hematology Parameter: Leukocyte Count

    Time frame: Baseline, at end of treatment (approximately Week 54)

  14. Change From Baseline in Serum Chemistry Parameter: Alkaline Phosphatase (ALP)

    Time frame: Baseline, at end of treatment (approximately Week 54)

  15. Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase (ALT)

    Time frame: Baseline, at end of treatment (approximately Week 54)

  16. Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase (AST)

    Time frame: Baseline, at end of treatment (approximately Week 54)

  17. Change From Baseline in Serum Chemistry Parameter: Total Bilirubin

    Time frame: Baseline, at end of treatment (approximately Week 54)

  18. Change From Baseline in Serum Chemistry Parameter: Lipase

    Time frame: Baseline, at end of treatment (approximately Week 54)

  19. Change From Baseline in Serum Chemistry Parameter: Amylase

    Time frame: Baseline, at end of treatment (approximately Week 54)

07

Results

Posted Aug 27, 2025

Participant flow

Participants took part in the study at 3 investigative sites in China from 28 November 2022 to 09 August 2024.

Participant flow — Overall Study
MilestoneBrentuximab Vedotin
Started10
Completed9
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryOverall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL

ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) that lasts at least 4 months. CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral involvement using computed tomography (CT) scan, and for the participants with mycosis fungoides (MF) only, detection of circulating Sezary cells. Response Criteria were based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines.

Time frame:
Up to 58 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL
percentage of participantsBrentuximab Vedotin
Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL60.0 (26.2 to 87.8)
SecondaryComplete Response (CR) Rate

CR rate is defined as the percentage of participants with CR. CR is defined as complete disappearance of all clinical evidence of disease. CR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using computed tomography (CT) scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.

Time frame:
Up to 58 weeks
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsBrentuximab Vedotin
Complete Response (CR) Rate0 (0 to 30.8)
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using CT scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.

Time frame:
Up to 58 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsBrentuximab Vedotin
Overall Response Rate (ORR)70.0 (34.8 to 93.3)
SecondaryDuration of Response (DOR)

Duration of response was assessed in participants with CR or PR and is defined as the time between first documentation of response and progressive disease (PD). Response criteria were based on ISCL, USCLC and EORTC Consensus guidelines. Participants who were lost to follow-up, withdrew consent, or discontinued treatment due to undocumented PD after the last adequate disease assessment were censored at the last disease assessment.

Time frame:
Up to 58 weeks
Reported as:
Median · months
Duration of Response (DOR)
monthsBrentuximab Vedotin
Duration of Response (DOR)NA (NA to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g. a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE and SAE were determined as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (up to approximately 58 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsBrentuximab Vedotin
TEAEs10
SAEs4
SecondaryChanges From Baseline in Participant's Vital Sign: Systolic and Diastolic Blood Pressure

Vital signs included seated blood pressure (systolic and diastolic) measurements.

Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · millimeters of mercury (mmHg)
Changes From Baseline in Participant's Vital Sign: Systolic and Diastolic Blood Pressure
millimeters of mercury (mmHg)Brentuximab Vedotin
Systolic Blood Pressure: Baseline125.6 ± 11.04
Systolic Blood Pressure: Change from Baseline at the End of Treatment-2.9 ± 8.81
Diastolic Blood Pressure: Baseline76.5 ± 6.36
Diastolic Blood Pressure: Change from Baseline at the End of Treatment-4.4 ± 4.61
SecondaryChanges From Baseline in Participant's Vital Sign: Heart Rate

Vital signs included heart rate (beats per minute) measurements.

Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · beats per minute
Changes From Baseline in Participant's Vital Sign: Heart Rate
beats per minuteBrentuximab Vedotin
Baseline87.4 ± 10.11
Change from Baseline at the End of Treatment-10.3 ± 14.34
SecondaryChanges From Baseline in Participant's Vital Sign: Body Temperature

Vital signs included body temperature (degree Celsius) measurements.

Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · degree Celsius (°C)
Changes From Baseline in Participant's Vital Sign: Body Temperature
degree Celsius (°C)Brentuximab Vedotin
Baseline36.62 ± 0.368
Change from Baseline at the End of Treatment0.00 ± 0.361
SecondaryNumber of Participants From Baseline to Worst Post-Baseline Assessment Categories Based on Eastern Cooperative Oncology Group (ECOG) Performance Status Scale

ECOG scale was used to assess performance status of participants. Grades range from 0 (fully active) to 5 (dead) where Grade 0: Normal activity. Grade 1: Symptoms but ambulatory. Grade 2: In bed \<50% of the time. Grade 3: In bed \>50% of the time. Grade 4: 100% bedridden. Grade 5: Dead. Lower grades indicate improvement. Reported here is the number of participants in each reported baseline grade to their worst post-baseline grade assessment on the ECOG scale.

Time frame:
Baseline up to 30 days after the last dose of study drug (up to approximately 58 weeks)
Reported as:
Count of participants · Participants
Number of Participants From Baseline to Worst Post-Baseline Assessment Categories Based on Eastern Cooperative Oncology Group (ECOG) Performance Status Scale
ParticipantsBrentuximab Vedotin
Participants with Baseline Grade: 0 to Worst Post-Baseline Grade: 02
Participants with Baseline Grade: 1 to Worst Post-Baseline Grade: 17
Participants with Baseline Grade: 1 to Worst Post-Baseline Grade: 31
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Hematology Parameter: Hemoglobin
grams per liter (g/L)Brentuximab Vedotin
Baseline126.3 ± 23.00
Change from baseline at the End of Treatment-5.4 ± 16.46
SecondaryChange From Baseline in Hematology Parameter: Neutrophil Count
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · 10^9 cells/liter (L)
Change From Baseline in Hematology Parameter: Neutrophil Count
10^9 cells/liter (L)Brentuximab Vedotin
Baseline3.949 ± 2.2230
Change from Baseline at the End of Treatment0.189 ± 4.4084
SecondaryChange From Baseline in Hematology Parameter: Platelet Count
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Hematology Parameter: Platelet Count
10^9 cells/LBrentuximab Vedotin
Baseline279.2 ± 78.24
Change from Baseline at the End of Treatment-97.0 ± 86.87
SecondaryChange From Baseline in Hematology Parameter: Lymphocyte Count
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Hematology Parameter: Lymphocyte Count
10^9 cells/LBrentuximab Vedotin
Baseline1.530 ± 0.7367
Change from Baseline at the End of Treatment-0.101 ± 0.3355
SecondaryChange From Baseline in Hematology Parameter: Leukocyte Count
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Hematology Parameter: Leukocyte Count
10^9 cells/LBrentuximab Vedotin
Baseline7.082 ± 3.1018
Change from Baseline at the End of Treatment-0.862 ± 3.5380
SecondaryChange From Baseline in Serum Chemistry Parameter: Alkaline Phosphatase (ALP)
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · Units per liter (U/L)
Change From Baseline in Serum Chemistry Parameter: Alkaline Phosphatase (ALP)
Units per liter (U/L)Brentuximab Vedotin
Baseline89.0 ± 29.66
Change from Baseline at the End of Treatment26.3 ± 36.10
SecondaryChange From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase (ALT)
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · U/L
Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase (ALT)
U/LBrentuximab Vedotin
Baseline18.9 ± 10.45
Change from Baseline at the End of Treatment8.2 ± 15.52
SecondaryChange From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase (AST)
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · U/L
Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase (AST)
U/LBrentuximab Vedotin
Baseline19.0 ± 5.85
Change from Baseline at the End of Treatment10.7 ± 10.40
SecondaryChange From Baseline in Serum Chemistry Parameter: Total Bilirubin
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · micromoles per liter (µmol/L)
Change From Baseline in Serum Chemistry Parameter: Total Bilirubin
micromoles per liter (µmol/L)Brentuximab Vedotin
Baseline8.82 ± 3.879
Change from Baseline at the End of Treatment1.93 ± 3.947
SecondaryChange From Baseline in Serum Chemistry Parameter: Lipase
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · U/L
Change From Baseline in Serum Chemistry Parameter: Lipase
U/LBrentuximab Vedotin
Baseline35.96 ± 10.726
Change from Baseline at the End of Treatment4.90 ± 11.837
SecondaryChange From Baseline in Serum Chemistry Parameter: Amylase
Time frame:
Baseline, at end of treatment (approximately Week 54)
Reported as:
Mean · U/L
Change From Baseline in Serum Chemistry Parameter: Amylase
U/LBrentuximab Vedotin
Baseline64.0 ± 24.55
Change from Baseline at the End of Treatment10.9 ± 25.80

Adverse events

Collected over Up to 58 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin0/10 (0%)4/10 (40%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventBrentuximab Vedotin
DysuriaRenal and urinary disorders1/10
Neuropathy peripheralNervous system disorders1/10
Oedema peripheralGeneral disorders1/10
Renal tubular necrosisRenal and urinary disorders1/10
White blood cell count decreasedInvestigations1/10
Most frequent other events
Showing 10 of 50
Most frequent other events
EventBrentuximab Vedotin
PyrexiaGeneral disorders4/10
AnaemiaBlood and lymphatic system disorders3/10
FatigueGeneral disorders3/10
Gamma-glutamyltransferase increasedInvestigations3/10
HypertriglyceridaemiaMetabolism and nutrition disorders3/10
Alanine aminotransferase increasedInvestigations2/10
AlopeciaSkin and subcutaneous tissue disorders2/10
Aspartate aminotransferase increasedInvestigations2/10
Blood alkaline phosphatase increasedInvestigations2/10
Blood creatine phosphokinase increasedInvestigations2/10

Baseline characteristics

The safety analysis set consisted of all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Brentuximab Vedotin
Mean57.1 ± 13.26
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin
Female5
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brentuximab Vedotin
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Takeda does not provide access to Individual Participant Data when a study is in a very limited (small) study population due to participant privacy concerns such as potential reidentification of study participants.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Aug 2024, 20 months.

Results were first posted in Aug 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 5, 2022
StartActual
Nov 28, 2022
Primary completionActual
Aug 9, 2024
CompletionActual
Aug 9, 2024
Results first posted
Aug 27, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05442554
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Nov 28, 2022
Primary completion
Aug 9, 2024
Completion
Aug 9, 2024
Results posted
Aug 27, 2025
Last update
Sep 18, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion